Patient diversity remains a problem in clinical trials. Although FDA-approved medicines serve a diverse population of Americans, participation in clinical trials remains predominantly white and male.
In this webinar segment, Robin Weinick, SVP & Managing Director, Americas and Global Program Officer for DIA, discusses the role played by our healthcare system. Americans in different states, cities, and communities do not have access to the same levels of healthcare. That discrepancy can lead to a distrust of physicians, insurers, health centers, and drug developers. Sponsors must overcome trust issues if they are to solve the patient diversity problem. Weinick discusses the lack of trust in the process, the Tuskegee experiments, and why communication is critical to overcoming these trust issues.